Skip Navigation



JAC Advance Access published online on December 14, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki445
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/2/339    most recent
dki445v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kern, W. V.
Right arrow Articles by Bohnert, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kern, W. V.
Right arrow Articles by Bohnert, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received August 30, 2005
Revised November 9, 2005
Accepted November 11, 2005

Brief report

Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli

Winfried V. Kern 1 *, Petra Steinke 1, Anja Schumacher 1, Sabine Schuster 1, Heike von Baum 2, and Jürgen A. Bohnert 1

1 Center for Infectious Diseases and Travel Medicine, Department of Medicine, University Hospital, Freiburg, Germany
2 Section of Hospital Hygiene, Department of Medical Microbiology and Hygiene, University of Ulm, Ulm, Germany

* To whom correspondence should be addressed.
Winfried V. Kern, E-mail: kern{at}if-freiburg.de


  Abstract

Objectives: 1-(1-Naphthylmethyl)-piperazine (NMP) has been shown to reverse multidrug resistance (MDR) in Escherichia coli overexpressing resistance-nodulation-cell division type efflux pumps, but there is no data on its activity in clinical isolates of E. coli.

Methods: The antimicrobial susceptibility of 60 clinical isolates of E. coli to a variety of antimicrobial agents was determined in the absence and presence of NMP and, for comparison, of Phe-Arg-{beta}-naphthylamide (PA{beta}N), another putative efflux pump inhibitor (EPI). The intracellular accumulation of ethidium bromide was measured to confirm efflux pump inhibition as the likely mechanism of action of NMP.

Results: Based on a 4-fold or greater reduction of the MIC after the addition of NMP in >50% of the isolates, significant effects of NMP at a concentration of 100 mg/L were seen for levofloxacin, linezolid and ethidium bromide. The ethidium bromide MIC changes after NMP addition correlated with differences in the ethidium bromide intracellular accumulation as measured by fluorometry in whole cell accumulation experiments. The activity of PA{beta}N was different from that of NMP, in particular regarding macrolide resistance reversal, suggesting different modes of action of the two putative EPIs.

Conclusions: NMP is moderately active in reversing MDR in clinical isolates of E. coli and can partially restore fluoroquinolone susceptibility through inhibition of efflux pumps.

Keywords: multidrug resistance; fluoroquinolones; nosocomial pathogens.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. M. Sierra, M. Ortega, C. Tarrago, C. Albet, J. Vila, J. Terencio, and A. Guglietta
Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant
J. Antimicrob. Chemother., November 1, 2009; 64(5): 990 - 992.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
X. R. Bina, J. A. Philippart, and J. E. Bina
Effect of the efflux inhibitors 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-{beta}-naphthylamide on antimicrobial susceptibility and virulence factor production in Vibrio cholerae
J. Antimicrob. Chemother., January 1, 2009; 63(1): 103 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Appl. Environ. Microbiol.Home page
M. Kvist, V. Hancock, and P. Klemm
Inactivation of Efflux Pumps Abolishes Bacterial Biofilm Formation
Appl. Envir. Microbiol., December 1, 2008; 74(23): 7376 - 7382.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Kumar, I. A. Khan, S. Koul, J. L. Koul, S. C. Taneja, I. Ali, F. Ali, S. Sharma, Z. M. Mirza, M. Kumar, et al.
Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus
J. Antimicrob. Chemother., June 1, 2008; 61(6): 1270 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Schumacher, R. Trittler, J. A. Bohnert, K. Kummerer, J.-M. Pages, and W. V. Kern
Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation
J. Antimicrob. Chemother., June 1, 2007; 59(6): 1261 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. A. Bohnert, S. Schuster, E. Fahnrich, R. Trittler, and W. V. Kern
Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF)
J. Antimicrob. Chemother., June 1, 2007; 59(6): 1216 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Mahamoud, J. Chevalier, S. Alibert-Franco, W. V. Kern, and J.-M. Pages
Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy
J. Antimicrob. Chemother., June 1, 2007; 59(6): 1223 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D.-H. Kwon and C.-D. Lu
Polyamine Effects on Antibiotic Susceptibility in Bacteria
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2070 - 2077.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Castanheira, A. S. Pereira, A. G. Nicoletti, A. C. C. Pignatari, A. L. Barth, and A. C. Gales
First Report of Plasmid-Mediated qnrA1 in a Ciprofloxacin-Resistant Escherichia coli Strain in Latin America
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1527 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Mesaros, Y. Glupczynski, L. Avrain, N. E. Caceres, P. M. Tulkens, and F. Van Bambeke
A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa
J. Antimicrob. Chemother., March 1, 2007; 59(3): 378 - 386.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Pannek, P. G. Higgins, P. Steinke, D. Jonas, M. Akova, J. A. Bohnert, H. Seifert, and W. V. Kern
Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-{beta}-naphthylamide
J. Antimicrob. Chemother., May 1, 2006; 57(5): 970 - 974.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.